Laza Medical Gets Up to $160M Series B Led by GE HealthCare

Laza Medical's first human cases gave its software a place alongside a cardiac procedure, with performance assessed retrospectively. That sequence matters for a company trying to give clinicians a more useful view of a moving heart: the development work begins by establishing what the image-guidance software can reliably tell the team.

The California company now has a larger financing framework behind that effort. Laza Medical announced up to $160M in structured Series B financing on November 4, 2026, led by GE HealthCare, with returning investors Unorthodox Ventures, PA MedTech and AMED participating. The funding supports its development of AI-powered robotic imaging for cardiovascular interventions, where imaging and the people interpreting it must stay coordinated throughout the case.

For cardiac-care teams, Laza's proposition is that better assistance with imaging could make specialized expertise easier to use across a procedure. The system remains under development and is not approved for commercial sale anywhere, leaving the financing attached to an engineering and clinical-development program rather than an established installed product. GE HealthCare's lead role also extends a relationship that began with its participation in Laza's earlier financing.

A strategic investor takes a larger role

GE HealthCare participated in Laza's $36M Series A, announced on December 12, 2023. The Capital Partnership led that round, with PA MedTech VC fund, Unorthodox Ventures and Dara Holdings also participating. The earlier funding supported product development and expansion of the team, establishing a documented financial relationship between Laza and an incumbent imaging company well before this Series B.

The progression from participant to lead gives the new transaction an institutional history. GE HealthCare is increasing its involvement in a company whose work concerns how imaging functions during an intervention. The significance lies in that continuing commitment to a specific clinical workflow; the announcement does not disclose an acquisition agreement, exclusive distribution arrangement or commercial launch date.

The financing description also deserves its full wording. Sidley, which represented Laza in the transaction, corroborates a structured financing of up to US$160M. Neither that notice nor the company announcement supplies the initial disbursement or conditions governing the full amount, so adding $160M to the earlier $36M would give readers an unsupported cash-raised total. The maximum commitment and the capital already received are separate accounting questions, and the disclosed record answers only the former for this round.

Building guidance around the clinical team

Laza's intended system brings together a real-time 3D heart model, procedural guidance, robotic probe control and a clinician-facing interface. Its target procedures include structural heart, electrophysiology and diagnostics. Those components address related tasks: acquiring an image, locating anatomy and devices, and giving the person performing the intervention useful guidance as the case develops.

The company's clinical history provides a more precise account of progress than the broad promise of robotic intervention. In its September 2025 software-only study announcement, Laza described software running concurrently with live procedures to support retrospective analysis and performance assessment. The company positioned that work as a step toward human testing of its complete intelligent robotic imaging system. A reader should keep those development stages distinct when judging how far the program has advanced.

For an operator evaluating the idea, the practical question is how imaging work gets shared. Laza wants to reduce the manual attention required to acquire and interpret useful views, allowing specialized staff to contribute where their expertise is most valuable. Any resulting gains in access, consistency or efficiency remain intended benefits; the disclosed financing is not a clinical outcome study. Hospitals would need evidence relevant to their patients and teams before translating the product ambition into an operating plan.

People carrying the system into practice

Amr Salahieh, Laza's founder and board chairman, is pursuing the company within the Shifamed medical-innovation portfolio. General Manager Pablo Garcia Kilroy brings a background that includes Johnson & Johnson and the development of Verb Surgical. Their current titles matter: the company identifies Garcia Kilroy as General Manager, and there is no basis here to assign him an undisclosed CEO role.

That combination of portfolio-building and robotics experience gives Laza a relevant foundation for the work ahead. Imaging assistance has to remain understandable to the people using it while software, hardware and the procedure interact. Engineering quality and clinical usability therefore meet inside the same product decision, rather than arriving as independent additions to an ultrasound image.

There is a commercial implication in that relationship. If Laza can deliver the assistance it describes, a hospital's evaluation would extend beyond image quality to the way responsibilities move through a care team. Training, coordination and confidence in the guidance would become part of the value discussion. These are considerations implied by the proposed workflow, not purchasing results or customer testimony established by the announcement.

The development work behind the financing

The Series B announcement connects the funding to intelligent imaging and the longer-term possibility of robotic interventions. It gives no basis for forecasting a clearance date, deployment count or revenue trajectory. The useful public milestones remain the capabilities Laza can demonstrate and the evidence it can produce as its program advances.

For GE HealthCare, the investment keeps an established imaging business close to a developing approach to procedural guidance. For Salahieh and Garcia Kilroy, the relationship now accompanies the work of bringing the software model, robotic control and clinical interface together. The next care team assessing Laza's system will encounter that work in the details of the case: what the image makes clear, how the guidance behaves, and where the clinician needs to put their attention.